Five Prime Therapeutics Inc., a South San Francisco-based biotechnology company, has entered into a drug discovery collaboration with U.K.-based biotechnology giant GlaxoSmithKline — the second collaboration of its kind between the two companies.
The collaboration will give GlaxoSmithKline exclusive access to therapeutic drugs developed by Five Prime for refractory asthma and chronic obstructive pulmonary disease.
No comments:
Post a Comment